HyFiDress aims at developing Excellence in the Research Area of Multifunctional Hybrid Hydrogel-Fibrous Constructs for Wound Dressings. This will be achieved by twinning the Warsaw University of Technology with outstanding EU institutions with high expertise in the areas of novel antimicrobial strategies and electrospinning. The activities undertaken as part of the project aim to increase the reputation, attractiveness and networking opportunities of CEZAMAT-PW, which will translate into the research and technological development of the Mazovian Voivodeship.
The impact of the project on the region will be significant and long-lasting, ultimately contributing to the transformation of the Mazovian Voivodeship into an intelligent and innovative health and life sciences region by promoting specialisation in the growing areas of electrospinning, antimicrobial wound dressings, difficult-to-treat infections and antimicrobial resistance. HyFiDress will allow the excellence development required for a consolidated strategic research approach and designing a set of guidelines for the exploitation and commercialization of the results that will have a strong regional, national and European impact. The proposal integrates synergies in complementary fields of research that include (large-scale) electrospinning technology, dual-function peptide development and microbiology, aiming to obtain scientific breakthroughs to improve the global health and economy.
HyFiDress aims will be achieved by twinning the Department of Medical Biotechnology and the Department of Microbiology, Molecular Genetics and Genomics of the Center for Advanced Materials and Technologies CEZAMAT of the Warsaw University of Technology (WUT) with outstanding EU institutions with high expertise in the areas of novel antimicrobial strategies and electrospinning. This challenge was addressed through a partnership of CEZAMAT-WUT with 3 leading EU research institutions: University Hospital Regensburg, in Regensburg, Germany, JUNIA, in Lille, France and biotechnology company Bioprex Medical B.V., in Groningen, Netherlands.
